BridgeBio Pharma Inc [BBIO] stock is trading at $64.5, up 1.48%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The BBIO shares have gain 18.65% over the last week, with a monthly amount glided 24.13%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Truist started tracking the stock with Buy rating on July 21, 2025, and set its price target to $66. On July 14, 2025, Jefferies initiated with a Buy rating and assigned a price target of $70 on the stock. Oppenheimer upgraded its rating to a Outperform but stick to its price target of $60 on July 09, 2025. Wolfe Research initiated its recommendation with a Outperform and recommended $49 as its price target on June 17, 2025. Redburn Atlantic started tracking with a Buy rating for this stock on March 31, 2025, and assigned it a price target of $50. In a note dated October 16, 2024, Scotiabank initiated an Sector Outperform rating.
BridgeBio Pharma Inc [BBIO] stock has fluctuated between $21.72 and $65.00 over the past year. Currently, Wall Street analysts expect the stock to reach $72.25 within the next 12 months. BridgeBio Pharma Inc [NASDAQ: BBIO] shares were valued at $64.5 at the most recent close of the market. An investor can expect a potential return of 12.02% based on the average BBIO price forecast.
Analyzing the BBIO fundamentals
BridgeBio Pharma Inc [NASDAQ:BBIO] reported sales of 235.81M for the trailing twelve months, which represents a growth of 4999.86%. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -2.78%, Pretax Profit Margin comes in at -3.31%, and Net Profit Margin reading is -3.29%. To continue investigating profitability, this company’s Return on Assets is posted at -0.72, Equity is 0.51 and Total Capital is -0.72. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-1.5.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 63.14 points at the first support level, and at 61.77 for the second support level. However, for the 1st resistance point, the stock is sitting at 65.24, and for the 2nd resistance point, it is at 65.97.
Ratios To Look Out For
For context, BridgeBio Pharma Inc’s Current Ratio is 5.19. Also, the Quick Ratio is 5.08, while the Cash Ratio stands at 4.26. Considering the valuation of this stock, the price to sales ratio is 52.29.
Transactions by insiders
Recent insider trading involved Frank McCormick, Director, that happened on Oct 27 ’25 when 1641.0 shares were purchased. Chief Executive Officer, Kumar Neil completed a deal on Oct 09 ’25 to sell 40000.0 shares. Meanwhile, Chief Executive Officer Kumar Neil sold 40000.0 shares on Oct 08 ’25.
